| Alicia Sharon Hettel, APRN | |
|
305 W Porphyry St Ste 1, Butte, MT 59701-2000 | |
| (406) 723-2961 | |
| Not Available |
| Full Name | Alicia Sharon Hettel |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 305 W Porphyry St Ste 1, Butte, Montana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013778893 | NPI | - | NPPES |
| Entity Name | Scl Health Medical Group-butte Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477869600 PECOS PAC ID: 2466633102 Enrollment ID: O20110301000023 |
News Archive
Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
In the July issue of European Urology, the scientific journal of the European Association of Urology, the significance and impact of focal therapy for low-risk cancer patients is discussed in a recent study by S. Eggener et al.
The Centers for Disease Control and Prevention (CDC) recently released an update on its polio eradication efforts.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alicia Sharon Hettel, APRN 305 W Porphyry St Ste 1, Butte, MT 59701-2000 Ph: (406) 723-2961 | Alicia Sharon Hettel, APRN 305 W Porphyry St Ste 1, Butte, MT 59701-2000 Ph: (406) 723-2961 |
News Archive
Anadys Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement to be acquired by Roche.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
In the July issue of European Urology, the scientific journal of the European Association of Urology, the significance and impact of focal therapy for low-risk cancer patients is discussed in a recent study by S. Eggener et al.
The Centers for Disease Control and Prevention (CDC) recently released an update on its polio eradication efforts.
› Verified 5 days ago